ERBB2 and breast cancer: However, a pooled analysis of 9 prospective breast cancer trials did report that positive predictors of locoregional recurrence after PST, included young age, positive clinical nodal status, higher tumour grade, HER2+ or triple negative disease subtype, and non-achievement of pCR [13].